# A Complement

# MicroVue<sup>™</sup> C5a EIA

Solutions for measurement of terminal complement pathway activation in experimental samples

### For Research Use Only. Not for use in Diagnostic Procedures.

C5a is generated as a result of cleavage of the terminal complement protein C5, during activation of the complement system via the classical, alternative or lectin pathway. The anaphylatoxin C5a itself is short-lived and in serum is cleaved rapidly into the more stable C5a des-Arg.

As a component of the terminal pathway and a potent anaphylatoxin, both C5a and C5a des-Arg perform many functions including mast cell degranulation,

chemotaxis and acts as a powerful inflammatory mediator. C5a may also play a role in hemo-incompatibility of biomaterials and in various disease states including myocardial infarction, stroke, kidney injury and infectious diseases.

The MicroVue C5a Enzyme Immunoassay detects both C5a and C5a des-Arg and is intended for investigations into the status and role of terminal complement pathway activation.

### **Performance**

Sensitivity

- ▶ LLOQ: 0.050 ng/mL
- ► LOD: 0.01 ng/mL

Inter assay CV

▶ < 9.5%

Intra assay CV

< 3.7%

**Excellent Reproducibility** 

Standardized to characterized AAA gold standard

### Ease of use

- Automatable on standard EIA analyzers
- No precipitation step

## Time to results

- ▶ Total assay time under 2.5 hours
- ▶ Hands-on time less than 30 min.

### **Features**

- Ready-to-use reagents
- Normal and Low Controls included
- Standards included

### **Product information**

- Direct Capture EIA
- ▶ 96 well format
- 40 tests/kit (in duplicate)
- For use with experimental samples including human plasma and serum
- ► Cat. # A021 RUO (U.S. and Canada) Cat. #A025 ROW

0083AI0609D (08/09)